Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia

TL;DR

This paper examines how long-acting injectable drugs like paliperidone palmitate help manage schizophrenia by reducing relapses and improving patients' quality of life.

Contribution

The paper presents case reports showing improved remission with monthly and three-monthly paliperidone palmitate formulations.

Findings

Paliperidone palmitate reduces relapses and improves remission in schizophrenia patients.

The drug shows better safety and tolerability across different patient ages.

It enhances social functioning and reduces the burden on healthcare systems and caregivers.

Abstract

This article discusses case reports of treatment with paliperidone palmitate in comparison with data from recent publications. Second-generation long-acting injectable antipsychotics have been shown to provide better control of psychiatric manifestations, reduce the severity of negative symptoms, improve social functioning and quality of life of patients and relatives, and reduce the burden of disease for both the healthcare system and the caregivers. The case reports presented in this article demonstrate better quality of remission in schizophrenia patients treated with one- monthly and three-monthly paliperidone palmitate formulations, due to higher effi in preventing relapses, better safety and good tolerability regardless of patient age.